^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cisplatin

    i
    Other names: L01XA01, L01 XA01, L01-XA01
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    REZILIENT4: A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (clinicaltrials.gov)
    P3, N=360, Recruiting, Taiho Oncology, Inc. | N=141 --> 360
    Enrollment change • Trial initiation date
    |
    EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • pemetrexed • zipalertinib (CLN-081)
    2d
    Targeting KIF23 inhibits cell proliferation and primary chemoresistance in cervical cancer by inactivating the MYH9/MCM2/PCNA pathway. (PubMed, Clin Transl Med)
    Cisplatin treatment induces KIF23 expression in a concentration- and time-dependent manner. KIF23 recruits USP7, which removes the K48-linked ubiquitin chain of MYH9, thereby stabilising MYH9 and facilitating its nuclear transport. MYH9 recruits USP15, thereby stabilising MCM2, which, in turn, regulates the G1/S phase transition by binding to PCNA. Targeting the KIF23/MYH9/MCM2/PCNA axis sensitises cervical cancer cells to cisplatin.
    Journal
    |
    MYH9 (Myosin Heavy Chain 9) • PCNA (Proliferating cell nuclear antigen) • KIF23 (Kinesin Family Member 23) • MCM2 (Minichromosome maintenance complex component 2) • USP7 (Ubiquitin Specific Peptidase 7)
    |
    cisplatin
    2d
    Synergistic Thermochemotherapy via Injectable Polyurethane Hydrogel Co-Delivering Cisplatin and 17AAG for Peritoneal Metastasis of Colorectal Cancer. (PubMed, Adv Healthc Mater)
    In conclusion, the safe, degradable CDDP/17AAG@PU system spreads to cover CRC-PM tumors at 37°C and gels rapidly at 43°C (clinical HIPEC temperature). It reduces antitumor drug induced hepatorenal toxicity, exerts good efficacy against CRC-PM and thus hold considerable potential for clinical translation.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    cisplatin
    2d
    ASP-1929-381: Study of the combination of the drug ASP-1929 and light illumination with the device PIT690 laser system in addition with pembrolizumab versus Standard of Care in the treatment of locoregional recurrent squamous cell carcinoma of the head and neck with no distant metastases (2025-523017-28-00)
    P2/3, N=30, Not yet recruiting, Rakuten Medical Inc.
    New P2/3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • Akalux (cetuximab sarotalocan)
    4d
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=854, Recruiting, AbbVie | Trial completion date: Nov 2036 --> Dec 2031 | Trial primary completion date: Nov 2036 --> Dec 2031
    Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
    4d
    TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (clinicaltrials.gov)
    P=N/A, N=34, Completed, Cairo University
    New trial
    |
    cisplatin
    4d
    IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=162, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)
    4d
    A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC (clinicaltrials.gov)
    P2, N=28, Completed, Asan Medical Center | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cisplatin • capecitabine • Ontruzant (trastuzumab-dttb)
    4d
    A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=223, Active, not recruiting, Eli Lilly and Company | Trial completion date: Aug 2026 --> Aug 2027
    Trial completion date
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel • lodapolimab (LY3300054) • LY3200882
    4d
    A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    cisplatin • carboplatin • Focus V (anlotinib) • etoposide IV • Andewei (benmelstobart)
    5d
    Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=48, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • emavusertib (CA-4948)